CPMD (Cannapharmarx) Growth Rank : 0 (As of Apr. 09, 2025)

View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Growth Rank?

Cannapharmarx has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Cannapharmarx Growth Rank Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannapharmarx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 3rd Street SW, Suite 3600, Calgary, AB, CAN, T2P 5C5

Website

https://www.cannapharmarx.com

Cannapharmarx Inc is involved in the cannabis sector. The company negotiates, acquires, and develops various cannabis cultivation projects throughout Canada. Its three projects include the Hanover Project; the Great Northern Project, and the Acquisition of Sunniva Medical.

Executives

Anthony Michael Panek	director	95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin	director, officer: Chief Executive Officer	C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels	officer: Chief Financial Officer	SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman	director	302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman	officer: Chief Operating Officer	1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson	director	977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick	10 percent owner	7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson	director	PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia	director, 10 percent owner	2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess	director	2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood	director	P.O. BOX 4375, DILLON CO 80435
James E Smeeding	director	4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife	director	9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule	director	C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920